

Message

---

**From:** Chalfant, Katherine [Chalfant.Katherine@epa.gov]  
**Sent:** 7/16/2021 12:07:29 PM  
**To:** Tallent, Robert [Tallent.Robert@epa.gov]  
**CC:** Bryant, Niki [bryant.niki@epa.gov]; Chalfant, Katherine [Chalfant.Katherine@epa.gov]  
**Subject:** RE: Submittal: Request for Correction - Toxicological Review of Chloroprene (CAS No. 126-99-8)

**Importance:** High

Thank you Niki!

Bob - - Please assigned an RFC number first thing on Monday morning, send your documents to Niki to make them 508 compliant and post to the web, and prepare the confirmation email for my signature.  
Also, please prepare the email for OMB.

Thank you both!

Katherine

---

**From:** Bryant, Niki <bryant.niki@epa.gov> **On Behalf Of** Quality  
**Sent:** Friday, July 16, 2021 7:23 AM  
**To:** Tallent, Robert <Tallent.Robert@epa.gov>  
**Cc:** Chalfant, Katherine <Chalfant.Katherine@epa.gov>  
**Subject:** FW: Submittal: Request for Correction - Toxicological Review of Chloroprene (CAS No. 126-99-8)  
**Importance:** High

Good Morning Bob,

We received the RFC in the Quality mailbox.

Niki

---

**From:** Walsh, Patrick <patrick-walsh@denka-pe.com>  
**Sent:** Thursday, July 15, 2021 6:09 PM  
**To:** Quality <Quality@epa.gov>  
**Subject:** Submittal: Request for Correction - Toxicological Review of Chloroprene (CAS No. 126-99-8)  
**Importance:** High

On behalf of Denka Performance Elastomer LLC, I respectfully submit the subject Request for Correction, comprised of 10 documents, all attached to this email. They include (specific filenames italicized and in parentheses):

Request for Correction document entitled: "Request for Correction - Toxicological Review of Chloroprene (CAS No. 126-99-8) In Support of Summary Information on the Integrated Risk Information System (IRIS)" (*Chloroprene RFC Letter 071521.pdf*)

Exhibit A: Report by Ramboll entitled "Incorporation of In Vitro Metabolism Data in a Physiologically Based Pharmacokinetic (PBPK) Model for Chloroprene- Revised Documentation in Response to USEPA Peer Review," and dated July 15, 2021. (*Exhibit A – Revised Chloroprene PBPK Model Documentation following EPA Peer Review\_07152021.pdf*)

Attachments to Exhibit A:

- Supplemental Materials A: Supplemental Tables (*Exhibit A – Supp Mat A – Supplemental Tables 07152021.pdf*)

- Supplemental Materials B: Re-estimation of Metabolism Parameters (*Exhibit A – Supp Mat B – Re-estimation of Metabolism Parameters 07152021.pdf*)
- Supplemental Materials C: IVIVE Literature Review (*Exhibit A – Supp Mat C – IVIVE Literature Review 07152021.pdf*)
- Supplemental Materials D: Metabolism Parameter Calculations (*Exhibit A – Supp Mat D – Metabolism Parameter Calculations 07152021.xlsx*)
- Supplemental Materials E: Model Files (*Exhibit A – Supp Mat E – Model Files 07152021.pdf*)
- Supplemental Materials F: Reactive Metabolite Modeling (*Exhibit A – Supp Mat F – Reactive Metabolite Modeling 07152021.pdf*)
- Supplemental Materials G: Responses to Peer Reviewer Comments (*Exhibit A – Supp Mat G – Responses to Peer Reviewer Comments 07152021.pdf*)

Exhibit B: Report by Ramboll entitled “Epidemiological Basis for Supporting a Correction of the Chloroprene Inhalation Unit Risk (IUR): Update,” dated July 15, 2021. (*Exhibit B – Updated Epidemiological Data and Studies 07152021.pdf*)

Thank you for your consideration. Please forward a receipt confirmation in reply to this email, and direct any questions to me using any of the contact methods below.



Patrick A. Walsh, CIH | SHE Manager  
 Denka Performance Elastomer LLC  
 560 Highway 44 | LaPlace, LA 70068  
 Office: 985-536-7573 | Cell: 251-321-5989  
[patrick-walsh@denka-pe.com](mailto:patrick-walsh@denka-pe.com)